ALPI

Across TCGA pan-cancer cohorts, ALPI Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ALPI data layer compared with 19 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ALPI Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALPI expression acts as an unfavorable survival marker.

LIHC, READ, and BLCA are the cancer types where ALPI Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.051	0.716	<.001	24	view →
READ	DFS	Median	All	0.255	0.844	.004	21	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
LUAD	OS	Median	II,III,IV	0.410	0.712	<.001	8	view →
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
LGG	DFS	Median	All	0.219	0.832	<.001	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ALPI–LIHC (OS)

Open the LIHC breakdown →